An SMA diagnosis is confirmed through a genetic blood test that detects deletions or mutations in the SMN1 gene. Spinal muscular atrophy is a genetic condition where nerve cells in the spinal cord progressively break down, leading to muscle weakness. The diagnostic process typically begins when a child shows signs like low muscle tone or missed motor milestones, though an increasing number of cases are now caught through newborn screening before symptoms ever appear.
How SMA Is Diagnosed
The primary diagnostic tool is a simple blood draw. The test looks for a missing or mutated SMN1 gene, which is responsible for producing a protein that keeps motor neurons alive. About 95% of all SMA cases involve a homozygous deletion, meaning both copies of the SMN1 gene are missing. This makes the genetic test highly reliable for confirming the diagnosis in one step.
The remaining 5% of cases are caused by a rare point mutation on one copy of the gene combined with a deletion on the other. Standard SMN1 testing won’t catch these, so if initial results come back negative but symptoms are strongly suggestive, a more detailed gene sequencing analysis can identify the mutation.
Older diagnostic methods like electromyography (EMG) and muscle biopsy were once the standard approach. Today, they’re largely unnecessary because genetic testing is faster, less invasive, and more specific. EMG is now reserved only for atypical cases or patients who test negative for both SMN1 deletion and mutation, where doctors need another way to look for signs of nerve damage in the muscles.
What Triggers the Diagnostic Process
For infants not identified through newborn screening, the path to diagnosis usually starts when a parent or pediatrician notices something wrong with muscle strength or movement. In the most severe form (type 1), symptoms appear within the first six months of life and can include limited head control, very low muscle tone (the baby feels “floppy”), absent reflexes, inability to sit without support, difficulty swallowing, and an abnormal breathing pattern with a bell-shaped chest.
Milder forms show up later. Type 2 typically becomes apparent between 6 and 18 months, while type 3 may not be recognized until a child is already walking and begins to struggle with stairs, running, or getting up from the floor. Type 4, the adult-onset form, is the rarest and mildest, with weakness beginning after age 18.
The gap between when symptoms first appear and when a diagnosis is confirmed can be significant. A systematic review of published studies found the average diagnostic delay was 3.6 months for type 1, 14.3 months for type 2, and 43.6 months for type 3. The milder the form, the longer it takes to pin down, because early symptoms can be subtle and overlap with many other conditions.
Newborn Screening
SMA has been added to the recommended uniform screening panel for newborns in the United States, and as of 2024, at least 19 states had implemented full population screening mandates. This is a major shift, because treatments for SMA work best when started before symptoms develop. A few drops of blood from a standard newborn heel prick can identify the SMN1 deletion, flagging the condition within days of birth.
Babies identified through screening are referred to a neuromuscular specialist, who determines the number of SMN2 gene copies the child carries. This is a critical next step, because SMN2 copy number is the strongest predictor of how severe the disease will be.
How SMN2 Copy Number Predicts Severity
Everyone has a backup gene called SMN2 that produces a small amount of the same protein the missing SMN1 gene would have made. The more copies of SMN2 a person has, the more backup protein their body can produce, and the milder the disease tends to be.
The general pattern looks like this:
- Type 1 (most severe): typically 1 to 2 SMN2 copies
- Type 2 (intermediate): typically 2 to 3 copies
- Type 3 (mild): typically 3 to 4 copies
- Type 4 (adult onset): typically 4 or more copies
This correlation is strong but not absolute. In a study of Colombian SMA patients, some individuals with 3 copies still developed type 1, while others with 3 copies had the milder type 3. Copy number gives clinicians a useful forecast, not a guarantee. This is one reason follow-up with a neuromuscular specialist matters: the clinical picture and the genetics together shape treatment decisions.
Conditions That Can Look Like SMA
Before genetic testing confirms SMA, doctors may need to consider other conditions that cause similar muscle weakness, particularly in infants. The list depends on the child’s age.
In newborns and babies under six months, conditions that can mimic SMA include Prader-Willi syndrome, congenital myotonic dystrophy, Pompe disease, congenital muscular dystrophies, and congenital myasthenic syndromes. In older children, Duchenne muscular dystrophy, Guillain-Barré syndrome, and botulism enter the picture. In adults presenting with progressive weakness, amyotrophic lateral sclerosis (ALS) and Kennedy disease are the primary considerations.
The good news is that genetic testing has simplified this process enormously. Rather than working through an extensive list of invasive tests, a single blood draw can either confirm SMA or rule it out, allowing the clinical team to redirect quickly if needed.
What Happens After a Positive Result
Once the genetic test confirms SMA, the recommended next step is referral to a neuromuscular specialist. This is true even for babies identified through newborn screening who appear completely healthy. Expert guidelines emphasize that a neuromuscular specialist, rather than a general pediatrician or even a general neurologist, is best positioned to manage the condition and coordinate treatment decisions.
The specialist will assess the child’s current motor function, count SMN2 copies if not already done, and discuss treatment options. Three approved therapies now exist for SMA, all aimed at increasing the amount of functional protein that motor neurons need to survive. The timing of treatment initiation is critical: starting before significant motor neuron loss occurs leads to substantially better outcomes, which is the entire rationale behind newborn screening programs.
For families receiving a prenatal or newborn diagnosis, the speed of modern genetic testing means the window for early intervention is wider than it has ever been. What was once a diagnosis that took months or years to confirm can now be identified within the first week of life.